ARTICLE | Company News
Regulus shares fall after clinical hold news
June 29, 2016 1:43 AM UTC
Regulus Therapeutics Inc. (NASDAQ:RGLS) plummeted $2.47 (49%) to $2.54 on Tuesday after announcing late Monday that FDA placed a full clinical hold on HCV candidate RG-101. Regulus has now reported two cases of jaundice, both severe adverse events, in patients treated with RG-101 (see BioCentury Extra, June 27). ...